Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
CCTG would like to say congratulations to our colleagues Ian Tannock and Natasha Leighl both from the Princess Margaret Cancer Centre for their recent recognition by ASCO as 2019 Leaders in Cancer Care
Allen S. Lichter Visionary Leader Award and Lecture
This award was created in honor of Allen. S. Lichter, MD, FASCO, to recognize ASCO members who have transformed the oncology field or significantly advanced the mission of ASCO, the Conquer Cancer Foundation, or CancerLinQ, LLC, through their leadership, vision, and ability to inspire.
We are very saddened to share that our esteemed colleague Dr. Stephen Couban passed away on March 19, 2019 at his home in Halifax.
Stephen was a remarkable leader, everyone at CCTG and across the network are grateful for the years of leadership he provided as the Co-Chair of the Hematology Disease Site Committee and Chair of the Leukemia Subcommittee.
The Canadian Cancer Trials Group 2019 Annual Spring Meeting will be held May 3 - 5, 2019 at the Chelsea Hotel in Toronto. Invitations have been sent and it is now time for you to register!
The CCTG Lay Representatives Committee has been renamed the Patient Representatives Committee.
Former cancer patient, Judy Needham is the Chair of the Canadian Cancer Trials Group (CCTG) Patient Representatives Committee (formerly Lay Committee). She talks about the role of the patient voice in the development of clinical trials. Before partnering with CCTG, Judy was a board member of the former BC chapter of the Canadian Breast Cancer Foundation, championing the first Breast Cancer Navigation Map, a patient tool aimed at simplifying the breast cancer journey. Since 2012, Ms.
Dr Daniel Renouf is the pancreatic cancer disease site chair and in this interview he discusses the PA7 trail which explores whether adding immunotherapy to chemotherapy can improve the efficacy or the positive effects of treatment for patients
HN10, A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma, is centrally activated.
